623 related articles for article (PubMed ID: 25003359)
21. Delayed fingolimod-associated asystole.
Espinosa PS; Berger JR
Mult Scler; 2011 Nov; 17(11):1387-9. PubMed ID: 21652609
[TBL] [Abstract][Full Text] [Related]
22. Fingolimod for relapsing multiple sclerosis: an update.
Horga A; Castilló J; Montalban X
Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
[TBL] [Abstract][Full Text] [Related]
23. Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects.
Kovarik JM; Hartmann S; Bartlett M; Riviere GJ; Neddermann D; Wang Y; Port A; Schmouder RL
Biopharm Drug Dispos; 2007 Mar; 28(2):97-104. PubMed ID: 17230596
[TBL] [Abstract][Full Text] [Related]
24. Oral fingolimod (FTY720) for relapsing multiple sclerosis.
Kappos L; Antel J; Comi G; Montalban X; O'Connor P; Polman CH; Haas T; Korn AA; Karlsson G; Radue EW;
N Engl J Med; 2006 Sep; 355(11):1124-40. PubMed ID: 16971719
[TBL] [Abstract][Full Text] [Related]
25. Fingolimod therapy for multiple sclerosis.
Willis MA; Cohen JA
Semin Neurol; 2013 Feb; 33(1):37-44. PubMed ID: 23709211
[TBL] [Abstract][Full Text] [Related]
26. Intensive Blood Pressure Reduction and Spot Sign in Intracerebral Hemorrhage: A Secondary Analysis of a Randomized Clinical Trial.
Morotti A; Brouwers HB; Romero JM; Jessel MJ; Vashkevich A; Schwab K; Afzal MR; Cassarly C; Greenberg SM; Martin RH; Qureshi AI; Rosand J; Goldstein JN;
JAMA Neurol; 2017 Aug; 74(8):950-960. PubMed ID: 28628707
[TBL] [Abstract][Full Text] [Related]
27. Predictors of outcome in warfarin-related intracerebral hemorrhage.
Zubkov AY; Mandrekar JN; Claassen DO; Manno EM; Wijdicks EF; Rabinstein AA
Arch Neurol; 2008 Oct; 65(10):1320-5. PubMed ID: 18852345
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
29. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
Széplaki G; Merkely B
Ideggyogy Sz; 2012 Nov; 65(11-12):369-76. PubMed ID: 23289171
[TBL] [Abstract][Full Text] [Related]
30. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
Montalban X; Comi G; O'Connor P; Gold S; de Vera A; Eckert B; Kappos L
Mult Scler; 2011 Nov; 17(11):1341-50. PubMed ID: 21727148
[TBL] [Abstract][Full Text] [Related]
31. Plasma d-dimer predicts poor outcome after acute intracerebral hemorrhage.
Delgado P; Alvarez-Sabín J; Abilleira S; Santamarina E; Purroy F; Arenillas JF; Molina CA; Fernández-Cadenas I; Rosell A; Montaner J
Neurology; 2006 Jul; 67(1):94-8. PubMed ID: 16832084
[TBL] [Abstract][Full Text] [Related]
32. Fingolimod for the treatment of relapsing multiple sclerosis.
Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
[TBL] [Abstract][Full Text] [Related]
33. Fingolimod for multiple sclerosis.
Drug Ther Bull; 2012 Feb; 50(2):18-20. PubMed ID: 22329953
[TBL] [Abstract][Full Text] [Related]
34. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
Huggins A; Sergott RC
Curr Opin Ophthalmol; 2011 Nov; 22(6):447-50. PubMed ID: 21946305
[No Abstract] [Full Text] [Related]
35. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
Tar L; Vécsei L
Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
[TBL] [Abstract][Full Text] [Related]
36. Oral fingolimod (gilenya) for multiple sclerosis.
Med Lett Drugs Ther; 2010 Dec; 52(1353-1354):98-9. PubMed ID: 21344782
[No Abstract] [Full Text] [Related]
37. Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use.
Minuk A; Belliveau MJ; Almeida DR; Dorrepaal SJ; Gale JS
JAMA Ophthalmol; 2013 Jun; 131(6):802-4. PubMed ID: 23599188
[No Abstract] [Full Text] [Related]
38. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
Kuhle J; Disanto G; Lorscheider J; Stites T; Chen Y; Dahlke F; Francis G; Shrinivasan A; Radue EW; Giovannoni G; Kappos L
Neurology; 2015 Apr; 84(16):1639-43. PubMed ID: 25809304
[TBL] [Abstract][Full Text] [Related]
39. Fingolimod alters inflammatory mediators and vascular permeability in intracerebral hemorrhage.
Li YJ; Chang GQ; Liu Y; Gong Y; Yang C; Wood K; Shi FD; Fu Y; Yan Y
Neurosci Bull; 2015 Dec; 31(6):755-62. PubMed ID: 25958190
[TBL] [Abstract][Full Text] [Related]
40. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
